Butt Amna Subhan, Sharif Fatima, Abid Shahab
Section of Gastroenterology, Department of Medicine, Aga Khan University Hospital, Karachi 74800, Pakistan.
World J Hepatol. 2018 Feb 27;10(2):267-276. doi: 10.4254/wjh.v10.i2.267.
Hepatocellular carcinoma (HCC) is a major cause of morbidity and mortality worldwide. Chronic hepatitis C virus infection (HCV) is the most common cause of HCC in many European countries, Japan and Pakistan. Introduction of the new direct acting antivirals (DAAs) has revolutionized the management of HCV worldwide, with high rates of sustained virologic response in patients who could not have tolerated the previous interferon based treatments. However, recently there have been reports raising caution about the long term effects of DAAs, particularly a possible increased risk of HCC. Therefore this review explores the current molecular studies as well as clinical data that investigate the impact of DAAs on occurrence and recurrence of HCC.
肝细胞癌（HCC）是全球发病和死亡的主要原因。慢性丙型肝炎病毒感染（HCV）是许多欧洲国家、日本和巴基斯坦HCC最常见的病因。新型直接作用抗病毒药物（DAAs）的引入彻底改变了全球HCV的治疗方式，使那些无法耐受以往基于干扰素治疗的患者实现了高持续病毒学应答率。然而，最近有报告对DAAs的长期影响提出了警示，尤其是HCC风险可能增加。因此，本综述探讨了当前研究DAAs对HCC发生和复发影响的分子研究以及临床数据。
